Hematology

The most recent data from CARTITUDE-4 were presented at the 2023 ASCO Meeting.

The assistant professor in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center discussed the real-world data she is presenting at EHA’s 2023 congress.

The associate professor at Medical College of Wisconsin discussed the rationale for the CARTITUDE-4 study and its latest updates.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The study has enrolled 17 patients as of May 2023 and enrollment is expected to complete by the end of 2024.

New overall survival analysis data on Yescarta from ZUMA-7 were presented at the ASCO 2023 meeting.

The associate professor at University College London also discussed unmet needs that remain in r/r B-ALL and another presentation of interest at ASCO’s 2023 conference.

Among 19 patients with r/r B-ALL included in the analysis, all 19 achieved a CR or CRi.

Safety findings were also improved when compared with the previous CARTITUDE-1 study, suggesting the therapy may be better tolerated in earlier lines of therapy.

The director of the Lymphoma Clinical Research Program at University of Texas MD Anderson Cancer Center discussed the implications of overall survival data that he presented at ASCO’s 2023 conference.

The associate professor in haemato-oncology at University College London discussed Autolus Therapeutics’ CAR-T, which utilizes a novel fast off-rate CD19 binding domain.

Among 94 patients who were treated with obe-cel in the trial, 76% achieved a CR or CRi.

Among 70 patients who were able to be evaluated for efficacy at 28 days or more, 91% achieved a complete response or a complete response with incomplete hematological recovery.

Among 49 patients who were included in the trial’s primary efficacy analysis set and received dose-level 2, the CR/CRi rate was 18.4%.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The senior scientist at Tune Therapeutics discussed preclinical research presented at the ASGCT 2023 meeting.

The principal investigator at Seattle Children’s Research Institute discussed her lab’s preclinical research on nonviral delivery methods for gene editing tools in the context of treating hemophilia A.

The principal investigator at Seattle Children’s Research Institute discussed the preclinical research on delivery methods for genomic medicines that her lab presented at ASGCT’s 2023 meeting.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The approval was based on data from the phase 1/2 EPCORE NHL-1 clinical trial.

The professor of internal medicine at UT Southwestern Medical Center shared his perspective on the current landscape of CAR-T cell therapy in the care of patients with myeloma.

All 8 patients with light chain amyloidosis who received HBI0101 responded.

Review top news and interview highlights from the week ending May 12, 2023.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Among 27 evaluated patients with relapsed/refractory B-cell acute lymphoblastic leukemia, 18 achieved a complete response.